Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$2.75B |
| 2 |
Coupang
CPNG
|
$1.09B |
| 3 |
Trade Desk
TTD
|
$793M |
| 4 |
BioNTech
BNTX
|
$736M |
| 5 |
Bilibili
BILI
|
$639M |
Top Sells
| 1 |
Tesla
TSLA
|
$7.41B |
| 2 |
Alphabet (Google) Class C
GOOG
|
$1.39B |
| 3 |
Meta Platforms (Facebook)
META
|
$880M |
| 4 |
Amazon
AMZN
|
$773M |
| 5 |
NIO
NIO
|
$619M |
Sector Composition
| 1 | Consumer Discretionary | 31.93% |
| 2 | Healthcare | 19.13% |
| 3 | Technology | 17.13% |
| 4 | Communication Services | 14.58% |
| 5 | Financials | 5.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
SolarEdge
SEDG
$2.04B
| $57K | ﹤0.01% |
200
+7
| +4% | +$2K |
|
277
Amkor Technology
AMKR
$6.09B
| $54K | ﹤0.01% |
+2,282
| New | +$54K |
|
|
SPWR
278
DELISTED
SunPower Corporation Common Stock
SPWR
| $53K | ﹤0.01% |
1,591
+105
| +7% | +$3.5K |
|
|
NEWR
279
DELISTED
New Relic, Inc.
NEWR
| $52K | ﹤0.01% |
840
+656
| +357% | +$40.6K |
|
|
SRNE
280
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $46K | ﹤0.01% |
5,531
+422
| +8% | +$3.51K |
|
281
Adeia
ADEA
$1.69B
| $45K | ﹤0.01% |
7,809
+192
| +3% | +$1.11K |
|
282
Coherent
COHR
$15.2B
| $45K | ﹤0.01% |
664
+30
| +5% | +$2.03K |
|
|
CSOD
283
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $45K | ﹤0.01% |
+1,043
| New | +$45K |
|
|
PS
284
DELISTED
Pluralsight, Inc. Class A Common Stock
PS
| $44K | ﹤0.01% |
+1,972
| New | +$44K |
|
285
Advanced Micro Devices
AMD
$245B
| $43K | ﹤0.01% |
546
+20
| +4% | +$1.58K |
|
286
Inspire Medical Systems
INSP
$2.56B
| $43K | ﹤0.01% |
208
+12
| +6% | +$2.48K |
|
287
Beam Therapeutics
BEAM
$2.11B
| $42K | ﹤0.01% |
519
+24
| +5% | +$1.94K |
|
288
Halozyme
HALO
$8.76B
| $42K | ﹤0.01% |
1,006
+52
| +5% | +$2.17K |
|
|
BPMC
289
DELISTED
Blueprint Medicines
BPMC
| $41K | ﹤0.01% |
+426
| New | +$41K |
|
|
GBT
290
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $41K | ﹤0.01% |
1,007
+57
| +6% | +$2.32K |
|
291
AppFolio
APPF
$10.2B
| $39K | ﹤0.01% |
277
+15
| +6% | +$2.11K |
|
292
Emergent Biosolutions
EBS
$404M
| $39K | ﹤0.01% |
423
+16
| +4% | +$1.48K |
|
293
Bristol-Myers Squibb
BMY
$96B
| $38K | ﹤0.01% |
607
+24
| +4% | +$1.5K |
|
|
ZNGA
294
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $35K | ﹤0.01% |
3,427
+146
| +4% | +$1.49K |
|
295
Synopsys
SNPS
$111B
| $34K | ﹤0.01% |
137
+9
| +7% | +$2.23K |
|
296
Varonis Systems
VRNS
$6.28B
| $33K | ﹤0.01% |
639
+24
| +4% | +$1.24K |
|
297
Pool Corp
POOL
$12.4B
| $32K | ﹤0.01% |
93
+3
| +3% | +$1.03K |
|
298
Pure Storage
PSTG
$25.9B
| $32K | ﹤0.01% |
1,470
+37
| +3% | +$805 |
|
299
Nektar Therapeutics
NKTR
$764M
| $31K | ﹤0.01% |
103
+2
| +2% | +$602 |
|
300
Opko Health
OPK
$1.07B
| $31K | ﹤0.01% |
+7,300
| New | +$31K |
|